Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 801–900 of 937
Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers
Mir, M. A., & Jan, U. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_10 · Cited by 4
ω-3 Polyunsaturated fatty acid enhance chemotherapy sensitivity by inhibiting NF-κB pathway
Liu, X., Yu, J., Wei-ming, K., Quan, W., Zhi-qiang, M., Hai-liang, F., Bei, G., & Yu-qin, L. (2010) · e-SPEN the European e-Journal of Clinical Nutrition and Metabolism · doi:10.1016/j.eclnm.2010.09.005 · Cited by 3
Activation of Janus Kinases During Tumorigenesis
Schmidt, J. W., & Wagner, K. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0891-8_15 · Cited by 3
Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer
Syn, N. L. X., Wee, I. J. Y., Wong, A. L.-A., Goh, R. M., Ow, S. G. W., Lambertini, M., & Lee, S. C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012919 · Cited by 3
Balasubramanian, P. K., Lee, Y., & Kim, Y. (2019) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11873 · Cited by 3
Cell Cycle Genes in a Mouse Mammary Hyperplasia Model
Said, T. K., & Medina, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023590.63974.f8 · Cited by 3
“In contrast, cyclin D1 knockout mice were resistant to breast cancers induced by the ras and neu oncogenes (42).”
BackgroundInfluentialNagasato, A. I., Murakami, K., Aoki, K., & Okada, M. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110865 · Cited by 2
Dey, D. K., Ganguly, K., Kujur, E., & Basak, S. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218314 · Cited by 3
Molecular Insights Into Phytochemicals as Modulators in Oral Squamous Cell Carcinoma
Nakhaei, A., Afshari, S., Hosseinzadeh, P., Mohtashami, E., Jalili‐Nik, M., Afshari, A. R., Kesharwani, P., & Sahebkar, A. (2026) · Oral Diseases · doi:10.1111/odi.70318 · Cited by 2
“This expression is redundant and overlapping (Yu et al. 2001).”
The role of C1orf50 in breast cancer progression and prognosis
Otani, Y., Tanaka, A., Maekawa, M., Peña, T., Rogachevskaya, A., Ando, T., Itano, T., Katayama, H., Nakata, E., Ozaki, T., et al. (2024) · Breast Cancer · doi:10.1007/s12282-024-01653-8 · Cited by 5
“The cyclin D:CDK4/6 complex is a factor that promotes breast cancer progression [22, 23], and CDK4/6 inhibitors have recently been administered to patients with unresectable or recurrent Luminal breast cancer [24, 25].”
Aktas, B. H., & Chen, T. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_9 · Cited by 5
Atypical cyclins in cancer: New kids on the block?
Quandt, E., Ribeiro, M. P. C., & Clotet, J. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.018 · Cited by 2
Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects
Li, X. (2022) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-022-02599-x · Cited by 2
The oncogene cyclin D1 promotes bipolar spindle integrity under compressive force
Sutanto, R., Neahring, L., Serra-Marques, A., Jacobo, M. J., Kilinc, S., Goga, A., & Dumont, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296779 · Cited by 2
Targeting Cyclin-Dependent Kinases for Cancer Therapy
Johnson, N., & Shapiro, G. I. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1770-6_11 · Cited by 2
G1 Phase Cyclins in Cancer Development and Progression
Alao, J. P. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-178-3_9 · Cited by 2
The Nucleolar Aspect of Breast Cancer
Yan, J., & Tang, D. (2013) · Springer eBooks · doi:10.1007/978-94-007-5818-6_12 · Cited by 2
Multistage Carcinogenesis: Cell and Animal Models
Kulesz-Martin, M. F., Gallegos, J. R., & Liu, Y. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01402-0 · Cited by 2
Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women
Bouzidi, L., Makni, S., Feki, J., Kallel, R., Graja, S., Gouiaa, N., Sellami‐Boudawara, T., & Mellouli, M. (2022) · Archives of Iranian Medicine · doi:10.34172/aim.2022.41 · Cited by 2
“10,40 In fact, cyclin D1 overexpression can be a predictor of poor prognosis.”
Beddok, A., Porte, B., Cottu, P. H., Fourquet, A., & Kirova, Y. (2023) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2022.11.003 · Cited by 2
Growth Factor Signaling Pathways in Cancer
Kalderon, D. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-664-5_9 · Cited by 2
Marino, S., Romelfanger, C., Yokota, Y., & Nusse, R. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-91 · Cited by 2
“However, when Wnt1 is expressed in Cyclin D1 -/- mice, only a slight reduction in tumorigenesis is observed [11], suggesting that the Wnt1 pathway also does not operate primarily through Cyclin D1.”
Andrechek, E. R., & Muller, W. J. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1127 · Cited by 2
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor α activity
Vogiatzi, P. (2007) · The Women s Oncology Review · doi:10.3109/14733400500304768 · Cited by 2
Molecular Biology of Breast Cancer
Caffarel, M. M., Pensa, S., Wickenden, J. A., & Watson, C. J. (2011) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0023164 · Cited by 2
Monitoring the Cell Cycle of Tumor Cells in Mouse Models of Human Cancer
Hammond, T., & Sage, J. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041383 · Cited by 3
Yang, Y., Zhu, S., Fu, Z., Sun, C., Yang, F., Zeng, T., Hua, Y., Bao, S., Gao, X., Huang, X., et al. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-54 · Cited by 1
“Mouse models lacking cyclin D1 and CDK4 prevent breast tumorigenesis (10,11).”
BackgroundTargeting Wnt Signalling in Cancer
Holik, A. Z., & Clarke, A. R. (2010) · Springer eBooks · doi:10.1007/978-1-4419-8023-6_8 · Cited by 1
“Supporting this notion, Cyclin D1 deficiency in a range of breast cancer mouse models has been shown to suppress the development of tumours driven by the Neu and Ras oncogenes, but not by c-Myc or Wnt-1 (Yu et al. 2001).”
BackgroundCyclin D1, Metabolism, and the Autophagy-Senescence Balance
Valenzuela, C. A., & Brown, N. E. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_5 · Cited by 2
Cell Cycle, DNA Damage Repair Systems, and Impact of Redox Regulation in Cancer
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_8 · Cited by 2
Zhao, L., Sun, Y., Yang, X., Tian, L., Li, L., Wang, F., Niu, X., Diao, L., & Li, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1433663 · Cited by 1
“…cell transition into S phase via phosphorylating the retinoblastoma protein, which leads to subsequent dissociation of E2F transcription factors and induction of S-phase gene expression (Giacinti and Giordano, 2006; O ’ leary et al., 2016; Yu et al., 2001; Yu et al., 2006; Zhu et al., 2013).”
BackgroundThe Tumor Pathology of Genetically Engineered Mice: Genomic Pathology
Cardiff, R. D. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_7 · Cited by 1
Zengel, B., Vardar, E., Postacı, H., KEÇECİLER, S., Alacacıoğlu, A., Deneçli, A. G., & Sakızlı, M. (2011) · Turkiye Klinikleri Journal of Medical Sciences · doi:10.5336/medsci.2010-17952 · Cited by 1
Genetische Grundlagen der Kanzerogenese
Bartram, C. R. (2009) · Springer eBooks · doi:10.1007/978-3-540-79725-8_4 · Cited by 4
Hyper sensitive protein detection by Tandem-HTRF reveals Cyclin D1 dynamics in adult mouse
Zampieri, A., Champagne, J., Auzemery, B., Fuentes, I., Maurel, B., & Bienvenu, F. (2015) · Scientific Reports · doi:10.1038/srep15739 · Cited by 2
Targeting the CDK4/6 Pathway in Breast Cancer
Malorni, L., Migliaccio, I., Guarducci, C., Bonechi, M., & Leo, A. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_69 · Cited by 1
Proteogenomic approach to drug targets in osteosarcomas with different original sites
Noguchi, R., Yoshimatsu, Y., Ono, T., Sei, A., & Kondo, T. (2021) · Journal of Electrophoresis · doi:10.2198/jelectroph.65.1 · Cited by 1
Mori, K., Oshima, Y., Nose, K., & Shibanuma, M. (2009) · Springer eBooks · doi:10.1007/978-4-431-88663-1_15 · Cited by 1
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma
LeBlanc, F., Hasanali, Z. S., Stuart, A., Shimko, S., Sharma, K., Leshchenko, V. V., Parekh, S. S., Fu, H., Zhang, Y., Martin, M. M., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28258 · Cited by 2
Role of Cell Cycle Control and Cyclin-Dependent Kinases in Breast Cancer
Senderowicz, A. M. (2002) · Breast Disease · doi:10.3233/bd-2002-15105 · Cited by 3
CDK Inhibitors as Anticancer Agents
Yap, T. A., Molife, L. R., & Bono, J. S. D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_6 · Cited by 2
Campi, V. (2007) · KOPS (University of Konstanz) · Cited by 1
Walker, K. (2005) · OakTrust (Texas A&M University Libraries) · Cited by 1
Dubus, P. R., Malumbres, M., & Ortega, S. (2006) · Enzyme inhibitors series/CRC enzyme inhibitors series · doi:10.1201/9781420005400.ch3 · Cited by 1
O’Connell, D. P., Adler, D., Kramer, F., & Ocker, M. (2020) · Wiley eBooks · doi:10.1002/9781119187547.ch15 · Cited by 1
Genetische Grundlagen der Kanzerogenese
Bartram, C. R. (2004) · Springer eBooks · doi:10.1007/978-3-662-06670-6_4 · Cited by 1
Scotting, P. J., & Appleby, V. J. (2004) · CRC Press eBooks · doi:10.1201/b13511-7 · Cited by 1
Characterization of the BTB/POZ protein ZBTB4 as a transcriptional regulator of cyclin D1
Doherty, P. W. (2012) · MacSphere (McMaster University) · doi:10.71548/15918 · Cited by 1
Raloxifene for the Treatment of Triple Negative Breast Cancer
Dzeyk, J. (2012) · Otago University Research Archive (University of Otago)
Participación del factor de necrosis tumoral alfa en la proliferación de carcinomas mamarios
Rivas, M. A. (2010) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Animal Models for Mechanistic Cancer Research
Wang, Z. (2003) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-08602-5_15
Targeting Cyclins to Cause Cancer Cell Apoptosis
Mazumder, S., Plesca, D. C., & Almasan, A. (2005) · Springer eBooks · doi:10.1007/1-4020-3302-8_6
Salah, Z., Grisaru‐Granovsky, S., Maoz, M., Uziely, B., Cohen, I., Turm, H., Peretz, T., & Bar‐Shavit, R. (2008) · Springer eBooks · doi:10.1007/978-0-387-09637-7_10 · Cited by 2
Cyclin A/CDK2 regulates multiple G2 phase pathways
Oakes, V. (2012)
Dias, M. H. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2012.tde-24052013-093639 · Cited by 3
The function of Tiam1 in tumor cell biology
Rygiel, T. P. (2009) · UvA-DARE (University of Amsterdam)
Na, K-ATPase as signaling transducer
Li, J. (2007) · Figshare · Cited by 3
Characterization and functional studies of PPM1D in breast cancer
Pärssinen, J. (2007) · Tampere University Institutional Repository (Tampere University)
The Cyclin D/Cyclin-dependent Kinase 4/6 Complex as a Target in the Treatment of Breast Cancer
Clark, A. S., & DeMichele, A. M. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-015-0189-9 · Cited by 1
Porquet, M. Z. (2010) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Lehn, S. (2013) · Lund University Publications (Lund University) · Cited by 1
McCormick, F. P. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00212-6
Effects of GHSC-73 on proliferation and cell cycle of human hepatocellular carcinoma HepG2 cells
Bo, F. E. N. G., Guo, Y., Huang, C., Li, L., & Jiao, B. (2009) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2009.01110
Papoutsis, A. J. (2012) · UA Campus Repository (The University of Arizona)
ROLE OF CELL-CELL ADHESION IN PROFILIN-1-DEPENDENT MODULATION OF BREAST CANCER CELL PROLIFERATION
Zou, L. (2009) · D-Scholarship@Pitt (University of Pittsburgh)
Role of CDK4 in Breast Development and Cancer
Reddy, H. K. D. L. (2006) · Defense Technical Information Center (DTIC) · doi:10.21236/ada462437
Kelley, A. L. (2000) · doi:10.15760/etd.1004
“Cyclin D1 has been widely investigated due to its role as a cell cycle modulator, and its ablation in breast cancer tissue has been shown to shut off proliferation in breast tumor cell lines (Yu et al. 2001).”
BackgroundApple Phytochemicals In The Prevention Of Breast Cancer: Effects On Cell Proliferation And Apoptosis
Felice, D. L. (2009) · eCommons (Cornell University)
Scafoglio, C., & Weisz, A. (2005) · Breast Cancer Online · doi:10.1017/s1470903105003214
Hormonelle und nichthormonelle Induktion der Apoptose bei menschlichen Mammakarzinomzellen in vitro
Hr, F. (2002) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Tao, J. (2010) · OhioLink ETD Center (Ohio Library and Information Network)
A New Perspective on Cyclin D1: Beyond Cell Cycle Regulation
Wang, C., Pestell, T. G., & Pestell, R. G. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-634-4_13
Merrill, M. A. L. (2008) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/xaqh-tj07
Suppression of mammary tumorigenesis by a Gemini vitamin D analog and a synthetic truterpenoid
So, J. Y. (2013) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3jw8ck7
“Moreover, cyclin D1-null mice showed remarkable resistance to mammary tumorigenesis driven by the NEU or RAS oncogene [314].”
BackgroundMeccanismi di controllo della proliferazione delle cellule germinali primordiali
Sorrentino, E. (2007) · Cineca Institutional Research Information System (Tor Vergata University) · doi:10.58015/sorrentino-eleonora_phd2007-05
Pulverer, B. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085032
Casimiro, M. C., Pestell, R. G., & Knudsen, E. S. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_13-4
Loomis, K. D. (2008) · Europe PMC (PubMed Central)
Deregulation of Cell Cycle Progression by Oncogenic Transformation
Rodríguez‐Puebla, M. L., Senderowicz, A. M., & Conti, C. J. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-313-2_8
Casimiro, M. C., & Crosariol, M. (2012)
Lees, J. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50007-5
McCormick, F. P. (2003) · Elsevier eBooks · doi:10.1016/b978-012124546-7/50593-3
Kinome-wide CRISPR-Cas9 screen to identify kinases involved in Taxol resistance in breast cancer
Montminy, T. (2016) · QSpace (Queen's University Library)
Li, X. (2006) · OakTrust (Texas A&M University Libraries)
Investigating the Role of PHIP1 in Breast Cancer
Lee, C. M. (2013) · TSpace (University of Toronto)
The Dawning of Translational Breast Cancer: From Bench to Bedside
Chen, X., Fan, S., & Song, E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_1 · Cited by 1
Бесова, Н. С. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-9-27-42 · Cited by 1
Birth and death of cellular senescence
Wang, B. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.131223530
Personalized Therapy for Cancer
Jain, K. K. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0769-1_10
Development of an Inhibitor of raf Kinase
McCormick, F. P. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-767-3_26
Downward, J. (2002) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1006699.84855
Kaufmann, M., von Minckwitz, G., & Costa, S. D. (2003) · Springer eBooks · doi:10.1007/978-3-662-11496-4_32
Kaufmann, M., von Minckwitz, G., Scharl, A. J., & Costa, S. D. (2006) · Springer eBooks · doi:10.1007/3-540-31105-x_31 · Cited by 3
Kaufmann, M., von Minckwitz, G., Scharl, A. J., Costa, S. D., & Linder, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-20923-9_35 · Cited by 1
Casimiro, M. C., Pestell, R. G., & Knudsen, E. S. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_13-5
Cyclin D ( CCND 1, 11 q 13; CCND 2, 12 p 13; CCND 3, 6 p 21)
(2004) · Encyclopedic Dictionary of Genetics, Genomics and Proteomics · doi:10.1002/0471684228.egp02996
Casimiro, M. C., Pestell, R. G., & Knudsen, E. S. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_13
Lee, T. H., Zhou, X. Z., & Lu, K. P. (2010) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a002516.01
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.